- Home
- EDIT vs PROK Comparison
EDIT vs PROK Comparison
Compare EDIT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | PROK |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.9M | 296.8M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDIT | PROK |
|---|---|---|
| Price | $2.91 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.30 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 1.3M | 784.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 132.64 | ★ 1075.00 |
| 52 Week Low | $1.43 | $0.54 |
| 52 Week High | $4.54 | $7.13 |
Technical Indicators
Market Signals| Indicator | EDIT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 40.14 |
| Support Level | $2.77 | $1.73 |
| Resistance Level | $3.17 | $2.58 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 28.00 | 12.07 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.